Observation device

... [Problem] To provide an observation device with which it is possible to obtain an excellent optical image by keeping contrast constant, while rendering unnecessary an operation for adjusting the distance from a phase-contrast microscope to an object to be observed. [Solution] This observation device 10 comprises a microscope 12. The microscope 12 comprises: an illumination light source 50; an illumination optical system 51; and an observation optical system 52 that forms an optical image of a to-be-observed object 28 from reflection light 62 obtained by illumination light 61 being reflected by the to-be-observed object 28. The observation optical system 52 comprises a phase plate 57 which, among the reflection light 62, changes the phase of direct reflection light 62A reflected by a reflection surface 49a. Both the illumination optical system 51 and the observation optical system 52 are positioned below the to-be-observed object 28. The observation device 10 comprises: an imaging element ...

PHARMACEUTICAL COMPOSITION FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS

The present invention pertains to a pharmaceutical composition for treating amyotrophic lateral sclerosis. More specifically, the present invention pertains to a pharmaceutical composition that is for treating amyotrophic lateral sclerosis and that is characterized by containing mesenchymal stem cells and being administered intravenously.

Pharmaceutical composition for preventing in-stent restenosis

The present invention relates to a pharmaceutical composition containing mesenchymal stem cells to be administered to a patient who has undergone stent implantation. Specifically, the present invention relates to: a pharmaceutical composition which is a pharmaceutical composition for tissue repair/regeneration characterized by containing mesenchymal stem cells and being administered to a patient who has undergone stent implantation; and the prevention of in-stent neointimal hyperplasia or in-stent restenosis by the pharmaceutical composition.

SYNAPSE FORMATION AGENT

The present invention relates to a synapse formation accelerant and a brain plasticity accelerant that contain CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow fluid, as well as to treatment of dementia, chronic cerebral infarctions, chronic spinal cord injuries, mental disorders, or the like using the aforementioned synapse formation accelerant and brain plasticity accelerant.

MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

MEDICAMENT FOR TREATING CEREBRAL INFARCTION

Provided is a novel means for: reducing the risk of cerebral hemorrhage as a result of recanalization therapy for occluded blood vessels (e.g., administration of medical drugs including thrombolytic agent, platelet aggregation inhibitor, and blood coagulation inhibitor, or physical removal of blood clots); and more effectively treating ischemic vascular disorders. The present invention is a mesenchymal stem cell-containing medical drug for treating ischemic vascular disorders, characterized by being concurrently used with recanalization therapy for occluded blood vessels. More specifically, the present invention is a medical drug for treating ischemic vascular disorders, characterized by reducing the risk of cerebral hemorrhage as a result of recanalization therapy for occluded blood vessels and by extending the period during which the medical drug can be applied.

OBSERVATION DEVICE

... [Problem] To provide an observation device with which it is possible to obtain an excellent optical image by keeping contrast constant, while rendering unnecessary an operation for adjusting the distance from a phase-contrast microscope to an object to be observed. [Solution] This observation device 10 comprises a microscope 12. The microscope 12 comprises: an illumination light source 50; an illumination optical system 51; and an observation optical system 52 that forms an optical image of a to-be-observed object 28 from reflection light 62 obtained by illumination light 61 being reflected by the to-be-observed object 28. The observation optical system 52 comprises a phase plate 57 which, among the reflection light 62, changes the phase of direct reflection light 62A reflected by a reflection surface 49a. Both the illumination optical system 51 and the observation optical system 52 are positioned below the to-be-observed object 28. The observation device 10 comprises: an imaging element ...

CELL FRACTION CONTAINING CELLS CAPABLE OF DIFFERENTIATING INTO NERVOUS SYSTEM CELLS

It is surprisingly found out that, when bone marrow cells are collected from mouse bone marrow and a monocyte fraction separated from these bone marrow cells is transplanted into a demyelinated rat model, the demyelinated neuraxon is re-myelinated. © KIPO & WIPO 2007 ...

Method for remyelinating a demyelinized lesion due to injury in the brain or spinal cord

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

Remedy for prion disease and method of producing the same

Cell fraction containing cells capable of differentiating into nervous system cells

PHARMACEUTICAL COMPOSITION FOR PREVENTING IN-STENT RESTENOSIS

The present invention relates to a pharmaceutical composition containing mesenchymal stem cells to be administered to a patient who has undergone stent implantation. Specifically, the present invention relates to: a pharmaceutical composition which is a pharmaceutical composition for tissue repair/regeneration characterized by containing mesenchymal stem cells and being administered to a patient who has undergone stent implantation; and the prevention of in-stent neointimal hyperplasia or in-stent restenosis by the pharmaceutical composition.

Pharmaceutical composition for treating amyotrophic lateral sclerosis

The present invention pertains to a pharmaceutical composition for treating amyotrophic lateral sclerosis. More specifically, the present invention pertains to a pharmaceutical composition that is for treating amyotrophic lateral sclerosis and that is characterized by containing mesenchymal stem cells and being administered intravenously.

MEDICINE FOR TISSUE REGENERATION, AND PREPARATION METHOD THEREFOR

The present invention pertains to a cell-based medicinal product containing mesenchymal stem cells, and a preparation method therefor. The present invention specifically pertains to a cell-based medicinal product containing mesenchymal stem cells, wherein: a) the mesenchymal stem cells express CX3CL1 in response to an inflammatory cytokine stimulus; and/or b) at least 90% of the mesenchymal stem cells express EGFR and/or ITGA4. The present invention also specifically pertains to a preparation method for a cell-based medicinal product containing mesenchymal stem cells, the method including: a) a step for adding inflammatory cytokines to a culture containing mesenchymal stem cells, and confirming that the mesenchymal stem cells express CX3CL1; and/or b) a step for confirming that at least 90% of the mesenchymal stem cells express EGFR and/or ITGA4.

Cell growth method and pharmaceutical preparation for tissue repair and regeneration

The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.

CELL GROWTH METHOD AND PHARMACEUTICAL PREPARATION FOR TISSUE REPAIR AND REGENERATION

The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.

MEDICAMENT FOR TREATING CEREBRAL INFARCTION

Title of Invention: MEDICAMENT FOR TREATING CEREBRAL INFARCTION Provided is new means for reducing risk of cerebral hemorrhage associated with a reperfusion therapy for vessel occlusion (for example, administration of a medicament including a thrombolytic agent, a platelet aggregation inhibitor, and an anticoagulant agent, or physical removal of a blood clot) and treating an ischemic vascular disorder more effectively. The present invention relates to a medicament for treating an ischemic vascular disorder, comprising mesenchymal stem cells, wherein the medicament is used in combination with a reperfusion therapy for vessel occlusion and more specifically, to a medicament for treating an ischemic vascular disorder, wherein the medicament reduces risk of cerebral hemorrhage associated with the reperfusion therapy for vessel occlusion and extends a time window in which the therapy is applicable. [No Suitable Figure] ...

METHOD FOR INDUCING DIFFERENTIATION OF MESODERMAL STEM CELLS, ES CELLS, OR IMMORTALIZED MESODERMAL STEM CELLS INTO NEURAL CELLS

Mesodermal stem cells or ES cells, prepared from the mononuclear cell fraction isolated from bone marrow fluid or umbilical blood, were found to differentiate into neural stem cells, neurons, or glial cells when cultured in a basal culture medium. In addition, the differentiation of the mesodermal stem cells or ES cells into neural cells was promoted through the addition of an ischemic brain extract to the above-mentioned basal culture medium. Furthermore, the neural cells obtained using the above-described method for inducing differentiation were revealed to have neural regeneration potency in a brain infarction model, a dementia model, a spinal cord injury model and a demyelination model. In addition, according to the present invention, mesodermal stem cells can be differentiated into neural cells by immortalizing the mesodermal stem cells by highly expressing or activating an immortalization gene in the mesodermal stem cells and culturing the cells under an appropriate condition. The ...

Cell growth method and pharmaceutical preparation for tissue repair and regeneration

Disclosed is a method for proliferating a cell collected from a living body ...

CELL PROLIFERATION METHOD, AND PHARMACEUTICAL AGENT FOR REPAIR AND REGENERATION OF TISSUE

Disclosed is a method for proliferating a cell collected from a living body in vitro rapidly and in a large quantity for the purpose of providing a safe and effective pharmaceutical agent for use in the repair/regeneration of a tissue of a living body. Specifically disclosed is a method for culturing a cell in a sample collected from a living body to proliferate the cell. It is preferred to carry out the method in a culture medium which has been determined as being negative for a serum cancer marker and/or an infection factor in advance and which contains a serum from the same species, and to adjust the quantity of an anticoagulant agent (e.g., heparin, a heparin derivative, or a salt of heparin or the heparin derivative) to be added to the collected sample to a quantity less than 5 U/mL of the volume of the sample or adjust the quantity of the anticoagulant agent to a quantity less than 0.5 U/mL in the culture medium before the culture is started. Also disclosed is use of the method.

METHOD OF INDUCING DIFFERENTIATION OF MESODERMAL STEM CELLS, ES CELLS OR IMMORTALIZED CELLS INTO NERVOUS SYSTEM CELLS

It is found out that, when mesodermal stem cells or ES cells prepared from mononuclear cell fraction separated from myeloid fluid or cord blood are cultured in a liquid fundamental culture medium, there arises induction of the differentiation of these mesodermal stem cells or ES cells into nerve stem cells, nerve cells or glial cells. It is also found out that the induction of the differentiation of the mesodermal stem cells or ES cells into nervous system cells is promoted by adding an ischemic brain extract to the liquid fundamental culture medium. It is further clarified that the nervous system cells thus obtained are capable of regenerating nerve in models of cerebral infarction, dementia, spinal injury and demyelination. Moreover, it becomes possible to induce the differentiation of mesodermal stem cells into nervous system cells by immortalizing the mesodermal stem cells by overexpressing or activating an immortalization gene therein and then culturing the cells under appropriate ...

MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. 1injecting an effective amount of cells capable of differentiating into neural cells or glia cells into a patient afflicted with epilepsy,. A method for treating epilepsy comprising:diluting marrow cells or cord blood cells;isolating a mononuclear cell fraction; andselecting cells having surface markers SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14(−), CD34(−), and CD45(−) from the mononuclear cell fraction, andwherein the cells are prepared by a method comprising: This application is a Divisional of U.S. patent application Ser. No. 13/040,954, filed Mar. 4, 2011, which is a Continuation of application Ser. No. 12/076,092, filed Mar. 13, 2008, which is a Continuation of application Ser. No. 11/189,050, filed Jul. 26, 2005, now abandoned, which is a Divisional of application Ser. No. 10/330,963, filed Dec. 23, 2002, now U.S. Pat. No. 7,098,027, which is a Continuation-In-Part of PCT/JP01/05456, filed Jun. 26, 2001, the contents of all of which are incorporated herein by reference in their entirety.The present invention relates to cells derived from bone marrow cells, cord blood cells, or embryonic hepatic tissues that can differentiate into neural cells, and cell fractions containing such cells. It is expected that these cells and cell fractions can be used to treat neurological diseases, particularly in autologous transplantation therapy.Transplantation of oligodendrocytes (i.e., oligodendroglia) (Archer D. R., et al., 1994. Exp. Neurol. 125:268-77; Blakemore W. F., Crang A. J., 1988. Dev. Neurosci. 10:1-11; Gumpel M., et al. 1987. Ann. New York Acad. Sci. 495:71-85) or myelin-forming cells, such as Schwann cells (Blakemore W. F., 1977. Nature 266:68-9; Blakemore W. F., Crang A. J., 1988. Dev. Neurosci. 10:1-11; Honmou 0. et al., 1996. J. Neurosci. 16:3199- ...

Synapse formation agent

The present invention relates to a synapse formation accelerant and a brain plasticity accelerant that contain CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow fluid, as well as to treatment of dementia, chronic cerebral infarctions, chronic spinal cord injuries, mental disorders, or the like using the aforementioned synapse formation accelerant and brain plasticity accelerant.

MEDICAMENT FOR TREATING CEREBRAL INFARCTION

Provided is a novel means for: reducing the risk of cerebral hemorrhage as a result of recanalization therapy for occluded blood vessels (e.g., administration of medical drugs including thrombolytic agent, platelet aggregation inhibitor, and blood coagulation inhibitor, or physical removal of blood clots); and more effectively treating ischemic vascular disorders. The present invention is a mesenchymal stem cell-containing medical drug for treating ischemic vascular disorders, characterized by being concurrently used with recanalization therapy for occluded blood vessels. More specifically, the present invention is a medical drug for treating ischemic vascular disorders, characterized by reducing the risk of cerebral hemorrhage as a result of recanalization therapy for occluded blood vessels and by extending the period during which the medical drug can be applied.

Cell growth method and pharmaceutical preparation for tissue repair and regeneration

Medicinal product for tissue regeneration, and preparation method therefor

The present invention pertains to a cell-based medicinal product containing mesenchymal stem cells, and a preparation method therefor. The present invention specifically pertains to a cell-based medicinal product containing mesenchymal stem cells, wherein: a) the mesenchymal stem cells express CX3CL1 in response to an inflammatory cytokine stimulus; and/or b) at least 90% of the mesenchymal stem cells express EGFR and/or ITGA4. The present invention also specifically pertains to a preparation method for a cell-based medicinal product containing mesenchymal stem cells, the method including: a) a step for adding inflammatory cytokines to a culture containing mesenchymal stem cells, and confirming that the mesenchymal stem cells express CX3CL1; and/or b) a step for confirming that at least 90% of the mesenchymal stem cells express EGFR and/or ITGA4.

Mesenchymal stem cell and a method of use thereof

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

MEDICAL CARE SELF-CELL DELIVERY SUPPORT SYSTEM, MEDICAL CARE SELF-CELL DELIVERY SUPPORT FINANCIAL SYSTEM, AND THEIR METHODS

A regeneration medicine support system in which in case of emergency a cure is brought effectively by infusing self-cells into the body quickly. A medical care self-cell delivery support system (100) preserves medical care self-cells collected from a member in a preservation means (34). When a delivery request receiving means (21) of the system receives from a member a self-cell delivery request including ID information and location information on the member, the system searches for the member information according to the ID information, and outputs the member information and the location information so as to deliver the self-cells from the preserving storage facility at the deliverer to the destination facility. If a plurality of preservation means exist at geographically different locations, the preservation means from which it takes the shortest time for delivery is selected based on the location information included in the delivery request. By using an ID information storage means ( ...

Autoserum-containing bone marrow cell culture system, autoserum-containing bone marrow cell culture method, and method for producing medicinal composition comprising autoserum-containing cultured bone marrow cells as active ingredient

To provide an autoserum-containing bone marrow cell culture system, whereby bone marrow cells, which are collected from a subject without using an anticoagulant, are subjected to an anticoagulation treatment using a medium in a liquid-tight state, cultured and then further cultured using the serum of said subject which is prepared in a liquid-tight state; an autoserum-containing bone marrow cell culture method; and a method for producing a medicinal composition which comprises, as the active ingredient, autoserum-containing cultured bone marrow cells. [Solution] An autoserum-containing bone marrow cell culture system for culturing bone marrow cells, which are collected from a subject without using an anticoagulant, using the serum of said subject, said system comprising a bone marrow cell suspension-storing device, a collected blood-storing device, an autoserum-acquiring device, and a bone marrow cell-culturing device.

REMEDY FOR INTERNAL ADMINISTRATION AGAINST CRANIAL NERVE DISEASES CONTAINING MESENCHYMAL CELLS AS THE ACTIVE INGREDIENT

By collecting bone marrow cells from rat bone marrow and intravenously administering the cells to a brain infarction model rat, it is found out that these cells are efficacious in treating brain infarction. It is also found out that human and mouse bone marrow stem cells have the same effect. Namely, mesenchymal cells such as bone marrow cells, umbilical cord blood cells or peripheral blood cells are usable as a drug for intravenous administration against cranial nerve diseases. © KIPO & WIPO 2007 ...

CELL GROWTH METHOD AND PHARMACEUTICAL PREPARATION FOR TISSUE REPAIR AND REGENERATION

The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method. 1. A method for tissue repair/regeneration comprising administering to a subject in need thereof an effective amount of mesenchymal stem cells ,wherein the mesenchymal stem cells were collected from bone marrow or blood without contact with an anticoagulant-effective amount of an anticoagulant, and culturing the collected mesenchymal stem cells in a medium comprising allogenic or autogenic serum,wherein the amount of any anticoagulant in the medium is less than an amount which is effective for anticoagulation during collection of the cells.2. The method according to claim 1 , wherein the cells are free from CD24 expression.3. The method according to claim 1 , wherein the medium has a serum content of 1 to 20% by volume.4. The method according to claim 1 , wherein the cells are human cells.5. The method according to claim 1 , wherein the cells are derived from the subject being treated.6. The method according to claim 1 , wherein the cells are administered intravenously claim 1 , via lumbar puncture claim 1 , intracerebrally claim 1 , intracerebroventricularly claim 1 , locally claim 1 , ...

LIFE EXTENSION AGENT

The present invention relates to a life extension agent containing CD24-negative mesenchymal stem cells and the treatment of dementia, cerebral infarction, spinal cord injury and the like using the life extension agent. 1. A method for extending a life of a subject , comprising administering CD24-negative mesenchymal stem cells to the subject.2. The method according to claim 1 , wherein the cells are positive for at least one or more selected from CD73 claim 1 , CD90 claim 1 , CD105 and CD200 and/or negative for at least one or more selected from CD19 claim 1 , CD34 claim 1 , CD45 claim 1 , CD74 claim 1 , CD79α and HLA-DR.3. The method according to claim 1 , wherein the cells are derived from bone marrow or blood.4. The method according to claim 3 , wherein the bone marrow or the blood is bone marrow or blood from the subject.5. The method according to claim 1 , wherein the cells have been proliferated in a culture medium comprising human serum.6. The method according to claim 5 , wherein the human serum is autologous serum from the subject.7. The method according to claim 1 , wherein the cells are administered to the subject by intravenous administration claim 1 , lumbar puncture administration claim 1 , intracerebral administration claim 1 , intraventricular administration claim 1 , a local administration or intraarterial administration.8. The method according to claim 1 , wherein the cells are administered by intravenous administration.9. The method according to claim 1 , wherein the cells have been proliferated and enriched in a culture medium containing no anticoagulant or less than 0.02 U/mL of an anticoagulant.10. The method according to claim 3 , wherein the bone marrow or the blood has been collected by adding an anticoagulant in an amount of less than 0.2 U/mL of the volume of the bone marrow or the blood.11. The method according to claim 9 , wherein the anticoagulant is heparin claim 9 , a heparin derivative or a salt thereof.12. The method according to ...

Mesenchymal stem cell and the method of use thereof

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

CELL FRACTION CONTAINING CELLS CAPABLE OF DIFFERENTIATING INTO NERVOUS SYSTEM CELLS

It is surprisingly found out that, when bone marrow cells are collected from mouse bone marrow and a monocyte fraction separated from these bone marrow cells is transplanted into a demyelinated rat model, the demyelinated neuraxon is re-myelinated. COPYRIGHT KIPO & WIPO 2010 ...

Cell preparation management method and system for use during cell preparation

To provide a cell preparation management method and system that prevent risks to living bodies by precisely managing, without mistakes, raw materials including resources such as an enormous number of containers that are handled during cell preparation. When cell preparation is performed in an aseptic operation area using raw materials including biologically derived raw materials and resources associated with samples, cell preparation instruction information associated with identification information such as raw material identification information and resource identification information is stored in an information processor. A wireless reader reads identification information provided to a wireless communication device attached to the raw materials conveyed into and out of the aseptic operation area. The information processor collates the read identification information with the corresponding identification information associated with the cell preparation instruction information, and outputs ...

Cell preservation container

MEDICINE FOR TISSUE REGENERATION, AND PREPARATION METHOD THEREFOR

The present invention relates to a cell-based medicine comprising mesenchymal stem cells, and a method for producing the same. More specifically, the present invention relates to: 1. A method for producing a cell-based medicine comprising mesenchymal stem cells , the method comprising the steps of:a) adding an inflammatory cytokine to a culture comprising mesenchymal stem cells, and confirming that the mesenchymal stem cells express CX3CL1; andb) confirming that 90% or more of the mesenchymal stem cells express EGFR and/or ITGA4.2. The method according to claim 1 , further comprising a step of confirming the ability to secrete one or more selected from BDNF claim 1 , VEGF claim 1 , and HGF in a culture comprising mesenchymal stem cells.3. The method according to claim 1 , wherein the inflammatory cytokine is one or more selected from the group consisting of TNF-α claim 1 , INFγ claim 1 , IL-1 claim 1 , IL-6 claim 1 , IL-8 claim 1 , IL-12 claim 1 , and IL-18.4. The method according to claim 1 , wherein the inflammatory cytokine includes TNF-α claim 1 , INFγ claim 1 , and IL-6.510.-. (canceled)11. A method for evaluating the ability of a cell-based medicine comprising mesenchymal stem cells to accumulate at a site of injury claim 1 , the method comprising a step of evaluating whether the expression of EGFR and/or ITGA4 in the mesenchymal stem cells is 90% or more.12. A method for evaluating the ability of mesenchymal stem cells for a cell-based medicine claim 1 , the method comprising the steps of:a) stimulating the mesenchymal stem cells with an inflammatory cytokine and determining the expression of CX3CL1 to evaluate the immunomodulatory ability of the cells; andb) determining whether the expression of EGFR and/or ITGA4 in the mesenchymal stem cells is 90% or more to evaluate the ability of the cells to accumulate at a site of injury.13. The method according to claim 12 , further comprising a step of confirming the ability to secrete one or more selected from BDNF ...

OBSERVATION DEVICE

MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

PHARMACEUTICAL COMPOSITION FOR PREVENTING IN-STENT RESTENOSIS

Cell growth method and pharmaceutical preparation for tissue repair and regeneration

Disclosed is a method for proliferating a cell collected from a living body in vitro rapidly and in a large quantity for the purpose of providing a safe and effective pharmaceutical agent for use in the repair/regeneration of a tissue of a living body. Specifically disclosed is a method for culturing a cell in a sample collected from a living body to proliferate the cell. It is preferred to carryout the method in a culture medium which has been determined as being negative for a serum cancer marker and/or an infection factor in advance and which contains a serum from the same species, and toadjust the quantity of an anticoagulant agent (e.g., heparin, a heparin derivative, or a salt of heparin or the heparin derivative) to be added to the collected sample to a quantity less than 5 U/mL of the volume of the sample or adjust the quantity of the anticoagulant agent to a quantity less than 0.5 U/mL in the culture medium before the culture is started. Also disclosed is use of the method.

Remedy for prion disease and method of producing the same

It is intended to provide a drug which is efficacious in treating a prion disease and has a high safety. A remedy for a prion disease which contains a mesenchymal stem cell as the active ingredient and a method of producing the same. A remedy for a prion disease which contains a mesenchymal stem cell, in particular, a mesenchymal stem cell having an anti-prion antibody gene transferred thereinto as the active ingredient and a method of producing the same. These remedies can not only prevent the progress of a prion disease but also contribute to the recovery of nerve dysfunction caused by the disease.

Cell fraction containing cells capable of differentiating into nervous system cells

Immortalized mesenchymal cells and utilization thereof

The method developed herein is for expanding cord blood-derived hematopoietic stem cells to a degree that is sufficiently safe for clinical application, such as the transplantation of hematopoietic stem cells into adult patients. Further, to prepare a number of mesenchymal stem cells or mesenchymal cells that have conventionally been available only in an extremely small number, an immortalizing gene such as that of telomerase is introduced alone into mesenchymal stem cells, mesenchymal cells or the like, so as to induce the differentiation of the expanded mesenchymal stem cells.

MEDICINE FOR TISSUE REGENERATION, AND PREPARATION METHOD THEREFOR

METHOD AND KIT FOR DETERMINING PROGNOSIS, REMOTE RECURRENCE RISK AND INVASION OF GLIOMA, AND PHARMACEUTICAL COMPOSITION FOR TREATING GLIOMA

[Problem] The present invention addresses the problem of providing a novel biomarker which makes it possible to find the prognosis of glioma, the risk of distant recurrence of glioma, the invasion ability of glioma cells and the like and also makes it possible to detect the prognosis, the risk, the invasion ability or the like in an earlier stage of a therapy of glioma. 12-. (canceled)3. A method for determining an invasion ability of a glioma cell , comprising:detecting ACTC1 protein and/or mRNA encoding ACTC1 protein in a sample containing a glioma cell; anddetermining that the glioma cell has high invasion ability when ACTC1 protein and/or mRNA encoding ACTC1 protein is detected.4. A method for determining presence of highly invasive glioma in a sample collected from a glioma lesion or a vicinity of the glioma lesion in a patient , comprising:detecting ACTC1 protein and/or mRNA encoding ACTC1 protein in the sample; anddetermining that the sample contains highly invasive glioma when ACTC1 protein and/or mRNA encoding ACTC1 protein is detected.512-. (canceled)13. A method for determining an invasion ability of glioma and treating the glioma , comprising:detecting ACTC1 protein and/or mRNA encoding ACTC1 protein in a sample containing glioma collected from a patient;determining that the glioma has high invasion ability when ACTC1 protein and/or mRNA encoding ACTC1 protein is detected; andtreating the glioma that is determined to have high invasion ability, by administering an effective amount of a substance that suppresses expression and/or function of ACTC1 protein or a pharmaceutical composition containing the substance to the patient.14. The method according to claim 13 , wherein the substance that suppresses expression and/or function of ACTC1 protein is an inhibitory nucleic acid against a gene encoding ACTC1 protein.15. The method according to claim 13 , wherein the substance that suppresses expression and/or function of ACTC1 protein is a recombinant virus ...

SYNAPSE FORMATION AGENT

SYNAPSE FORMATION AGENT The present invention relates to a synapse formation promoter and a brain plasticity promoter comprising CD24- negative mesenchymal stem cells prepared from a patient's own bone marrow aspirate and treatment of dementia, chronic-phase cerebral infarction, chronic-phase spinal cord injury, mental diseases, and the like using the synapse formation promoter and brain plasticity promoter. [No Suitable Figure] ...

MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. 1diluting marrow cells or cord blood cells;isolating a mononuclear cell fraction; andselecting cells having surface markers SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14(−), CD34(−), and CD45(−) from the mononuclear cell fraction,wherein said selected cells are capable of differentiating into neural cells or glia cells.. A method for preparing a mononuclear cell fraction, comprising: This application is a Divisional of U.S. patent application Ser. No. 13/040,954, filed Mar. 4, 2011, which is a Continuation of application Ser. No. 12/076,092, filed Mar. 13, 2008, which is a Continuation of application Ser. No. 11/189,050, filed Jul. 26, 2005, now abandoned, which is a Divisional of application Ser. No. 10/330,963, filed Dec. 23, 2002, now U.S. Pat. No. 7,098,027, which is a Continuation-In-Part of PCT/JP01/05456, filed Jun. 26, 2001, the contents of all of which are incorporated herein by reference in their entirety.The present invention relates to cells derived from bone marrow cells, cord blood cells, or embryonic hepatic tissues that can differentiate into neural cells, and cell fractions containing such cells. It is expected that these cells and cell fractions can be used to treat neurological diseases, particularly in autologous transplantation therapy.Transplantation of oligodendrocytes (i.e., oligodendroglia) (Archer D. R., et al., 1994. Exp. Neurol. 125:268-77; Blakemore W. F., Crang A. J., 1988. Dev. Neurosci. 10:1-11; Gumpel M., et al. 1987. Ann. New York Acad. Sci. 495:71-85) or myelin-forming cells, such as Schwann cells (Blakemore W. F., 1977. Nature 266:68-9; Blakemore W. F., Crang A. J., 1988. Dev. Neurosci. 10:1-11; Honmou O. et al., 1996. J. Neurosci. 16:3199-208), or olfactory ensheating cells (Franklin R. J. et al., 1996. Glia 17:217-24; ...

SYNAPSE FORMATION AGENT

The present invention relates to a synapse formation promoter and a brain plasticity promoter comprising CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow aspirate and treatment of dementia, chronic-phase cerebral infarction, chronic-phase spinal cord injury, mental diseases, and the like using the synapse formation promoter and brain plasticity promoter.

PHARMACEUTICAL COMPOSITION FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS

Cell growth method and pharmaceutical preparation for tissue repair and regeneration

The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.

MEDICAMENT FOR TREATING CEREBRAL INFARCTION

Provided is new means for reducing risk of cerebral hemorrhage associated with a reperfusion therapy for vessel occlusion (for example, administration of a medicament including a thrombolytic agent, a platelet aggregation inhibitor, and an anticoagulant agent, or physical removal of a blood clot) and treating an ischemic vascular disorder more effectively. The present invention relates to a medicament for treating an ischemic vascular disorder, comprising mesenchymal stem cells, wherein the medicament is used in combination with a reperfusion therapy for vessel occlusion and more specifically, to a medicament for treating an ischemic vascular disorder, wherein the medicament reduces risk of cerebral hemorrhage associated with the reperfusion therapy for vessel occlusion and extends a time window in which the therapy is applicable. 1. A method for treating an ischemic vascular disorder , comprising administering mesenchymal stem cells to a subject in need thereof , wherein the method is combined with a reperfusion therapy for vessel occlusion.2. The method according to claim 1 , wherein the risk of cerebral hemorrhage associated with the reperfusion therapy for vessel occlusion is reduced by administering the mesenchymal stem cells.3. The method according to claim 1 , wherein the reperfusion therapy for vessel occlusion comprises any one or more selected from administration of a thrombolytic agent claim 1 , a platelet aggregation inhibitor claim 1 , and an anticoagulant agent claim 1 , and physical removal of a blood clot.4. The method according to claim 1 , wherein the reperfusion therapy for vessel occlusion comprises administration of the thrombolytic agent.5. The method according to claim 4 , wherein the thrombolytic agent is plasminogen activator.6. The method according to claim 3 , wherein a time window in which the thrombolytic agent can be administered is extended by administering the mesenchymal stem cells.7. The method according to claim 1 , wherein the ...

Therapeutic autologous-cell delivery support system, financial system for use therewith, and method therefor

Disclosed is a therapeutic autologous-cell delivery support system 100, in which a therapeutic autologous cell extracted from a member is reserved in reserve means 34, and an autologous-cell delivery request from the member which includes ID information and positional information is received. Membership information is retrieved in accordance with the received ID information, and the membership information and positional information of the member is output. When the reserve means is provided in plural number at geographically different locations, one reserve means having a shortest delivery time is selected in accordance with the positional information included in the delivery request. The delivery request can be issued using ID information storage means 11 for transmitting the ID information, in a simple operation, or automatically issued using a monitor of physical data.

Method of inducing differentiation of mesodermal stem cells, ES cells or immortalized cells into nervous system cells

Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient

Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

Autoserum-containing bone marrow cell culture system, autoserum-containing bone marrow cell culture method, and method for producing medicinal composition comprising autoserum-containing cultured bone marrow cells as active ingredient

To provide an autoserum-containing bone marrow cell culture system, whereby bone marrow cells, which are collected from a subject without using an anticoagulant, are subjected to an anticoagulation treatment using a medium in a liquid-tight state, cultured and then further cultured using the serum of said subject which is prepared in a liquid-tight state; an autoserum-containing bone marrow cell culture method; and a method for producing a medicinal composition which comprises, as the active ingredient, autoserum-containing cultured bone marrow cells. [Solution] An autoserum-containing bone marrow cell culture system for culturing bone marrow cells, which are collected from a subject without using an anticoagulant, using the serum of said subject, said system comprising a bone marrow cell suspension-storing device, a collected blood-storing device, an autoserum-acquiring device, and a bone marrow cell-culturing device.

CELL GROWTH METHOD AND PHARMACEUTICAL PREPARATION FOR TISSUE REPAIR AND REGENERATION

The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.

Internally administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient

Intravenous administration of bone marrow cells collected from rat bone marrow to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

Cell fractions containing cells capable of differentiating into neural cells

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

AUTOSERUM-CONTAINING BONE MARROW CELL CULTURE SYSTEM, AUTOSERUM-CONTAINING BONE MARROW CELL CULTURE METHOD, AND METHOD FOR PRODUCING MEDICINAL COMPOSITION COMPRISING AUTOSERUM-CONTAINING CULTURED BONE MARROW CELLS AS ACTIVE INGREDIENT

To provide an autoserum-containing bone marrow cell culture system, whereby bone marrow cells, which are collected from a subject without using an anticoagulant, are subjected to an anticoagulation treatment using a medium in a liquid-tight state, cultured and then further cultured using the serum of said subject which is prepared in a liquid-tight state; an autoserum-containing bone marrow cell culture method; and a method for producing a medicinal composition which comprises, as the active ingredient, autoserum-containing cultured bone marrow cells. [Solution] An autoserum-containing bone marrow cell culture system for culturing bone marrow cells, which are collected from a subject without using an anticoagulant, using the serum of said subject, said system comprising a bone marrow cell suspension-storing device, a collected blood-storing device, an autoserum-acquiring device, and a bone marrow cell-culturing device. 1. An autoserum-containing bone marrow cell culture system for culturing bone marrow cells collected from a subject without use of an anticoagulant with the serum of the subject , comprising:a bone marrow cell suspension storing device which mixes a bone marrow fluid containing bone marrow cells collected from the subject with a medium in a liquid-tight state at the site of collection and stores an anticoagulated bone marrow cell suspension obtained by mixing of the bone marrow fluid with the medium, anda bone marrow cell culturing device which cultures the bone marrow cells contained in the bone marrow cell suspension transferred from the bone marrow cell suspension storing device and performs further culture of the bone marrow cells in the bone marrow cell suspension which the culture supernatant is removed from and, a medium and the serum of the subject are added to after a lapse of a predetermined culture period.2. The autoserum-containing bone marrow cell culture system according to claim 1 , comprising at least one of the following devices (a) ...

Mesenchymal stem cell and a method of use thereof

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

PHARMACEUTICAL COMPOSITION FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS

The present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis. More specifically, the present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis, wherein the pharmaceutical composition comprises mesenchymal stem cells and is intravenously administered.

AUTOSERUM-CONTAINING BONE MARROW CELL CULTURE SYSTEM, AUTOSERUM-CONTAINING BONE MARROW CELL CULTURE METHOD, AND METHOD FOR PRODUCING MEDICINAL COMPOSITION COMPRISING AUTOSERUM-CONTAINING CULTURED BONE MARROW CELLS AS ACTIVE INGREDIENT

To provide an autoserum-containing bone marrow cell culture system, whereby bone marrow cells, which are collected from a subject without using an anticoagulant, are subjected to an anticoagulation treatment using a medium in a liquid-tight state, cultured and then further cultured using the serum of said subject which is prepared in a liquid-tight state; an autoserum-containing bone marrow cell culture method; and a method for producing a medicinal composition which comprises, as the active ingredient, autoserum-containing cultured bone marrow cells. [Solution] An autoserum-containing bone marrow cell culture system for culturing bone marrow cells, which are collected from a subject without using an anticoagulant, using the serum of said subject, said system comprising a bone marrow cell suspension-storing device, a collected blood-storing device, an autoserum-acquiring device, and a bone marrow cell-culturing device. 113-. (canceled)14. A method for preparing cultured bone marrow cells from a subject without use of an anticoagulant , comprising:(a) collecting at a site of the subject a bone marrow fluid in a liquid-tight state, wherein the collected bone marrow fluid comprises bone marrow cells;(b) mixing the collected bone marrow fluid with a first culture medium in a liquid-tight state at the site of collection, wherein the first culture medium is in an amount 1.5 times to 6 times the amount of the collected bone marrow fluid, whereby an anticoagulated bone marrow cell suspension comprising the bone marrow cells is prepared;(c) transporting the anticoagulated bone marrow cell suspension in a suspended state to a location of cell culture; and(d) culturing the bone marrow cells from the anticoagulated bone marrow cell suspension in a bone marrow cell culture vessel at the location of cell culture, whereby the cultured bone marrow cells are prepared.15. The method of claim 14 , wherein the culturing step is performed in the presence of a serum of the subject.16. ...

MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. 1. (canceled)2. A cell population isolated from bone marrow or cord blood comprising mesenchymal stem cells ,wherein said mesenchymal stem cells are SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14(−), CD34(−), and CD45(−), andwherein cells within said cell population are capable of differentiating into neurons or glia cells.3. A method for treating neurodegeneration , comprisingisolating a cell population from bone marrow,wherein said cell population comprises mesenchymal stem cells that are SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14(−), CD34(−), and CD45(−) and said isolation does not exclude hematopoietic cells from said cell population; andinjecting an effective amount of said isolated cell population into a patient in need of said treatment,wherein said effective amount of said isolated cell population is effective at treating said patient's neurodegeneration.4. A method for treating a demyelinating disorder claim 2 , which comprises injecting claim 2 , recipient claim 2 , the cell population according to .5. A method for treating a brain tumor claim 2 , which comprises injecting claim 2 , into a recipient claim 2 , the cell population according to .6. A method for treating epilepsy claim 2 , which comprises injecting claim 2 , into a recipient claim 2 , the cell population according to .7. A mononuclear cell fraction comprising cells capable of differentiating into neurons or glia cells claim 2 , wherein said fraction is prepared byobtaining bone marrow cells or cord blood cells,diluting the bone marrow cells,separating a mononuclear cell fraction,collecting said mononuclear cell fraction.8. A method for treating a neurodegenerative disorder claim 7 , which comprises injecting claim 7 , into a recipient claim 7 , the mononuclear cell fraction according ...

Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient

Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

Internally administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient

Intravenous administration of bone marrow cells collected from rat bone marrow to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient

Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

Method for inducing differentiation of mesodermal stem cells, es cells, or immortalized mesodermal stem cells into neural cells

It is found out that, when mesodermal stem cells or ES cells prepared from mononuclear cell fraction separated from myeloid fluid or cord blood are cultured in a liquid fundamental culture medium, there arises induction of t he differentiation of these mesodermal stem cells or ES cells into nerve stem cells, nerve cells or glial cells. It is also found out that the induction o f the differentiation of the mesodermal stem cells or ES cells into nervous system cells is promoted by adding an ischemic brain extract to the liquid fundamental culture medium. It is further clarified that the nervous system cells thus obtained are capable of regenerating nerve in models of cerebral infarction, dementia, spinal injury and demyelination. Moreover, it becomes possible to induce the differentiation of mesodermal stem cells into nervous system cells by immortalizing the mesodermal stem cells by overexpressing or activating an immortalization gene therein and then culturing the cells unde r appropriate conditions. This method is highly useful in nerve regeneration therapy.

Medical drug for treating cerebral infarction

Observation device

Cell fractions containing cells capable of differentiating into neural cells

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

Remedy for prion disease and method of producing the same

It is intended to provide a drug which is efficacious in treating a prion disease and has a high safety. A remedy for a prion disease which contains a mesenchymal stem cell as the active ingredient and a method of producing the same. A remedy for a prion disease which contains a mesenchymal stem cell, in particular, a mesenchymal stem cell having an anti-prion antibody gene transferred thereinto as the active ingredient and a method of producing the same. These remedies can not only prevent the progress of a prion disease but also contribute to the recovery of nerve dysfunction caused by the disease.

Immortalized mesenchymal cells and utilization thereof

Cell fractions containing cells capable of differentiating into neural cells

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

Immortalized mesenchymal cells and utilization thereof

The method developed herein is for expanding cord blood-derived hematopoietic stem cells to a degree that is sufficiently safe for clinical application, such as the transplantation of hematopoietic stem cells into adult patients. Further, to prepare a number of mesenchymal stem cells or mesenchymal cells that have conventionally been available only in an extremely small number, an immortalizing gene such as that of telomerase is introduced alone into mesenchymal stem cells, mesenchymal cells or the like, so as to induce the differentiation of the expanded mesenchymal stem cells.

Internallly administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient

By collecting bone marrow cells from rat bone marrow and intravenously administering the cells to a brain infarction model rat, it is found out that these cells are efficacious in treating brain infarction. It is also found out that human and mouse bone marrow stem cells have the same effect. Namely, mesenchymal cells such as bone marrow cells, umbilical cord blood cells or peripheral blood cells are usable as a drug for intravenous administration against cranial nerve diseases.

Remedy for internal administration against cranial nerve diseases containing mesenchymal cells as the active ingredient

By collecting bone marrow cells from rat bone marrow and intravenously administering the cells to a brain infarction model rat, it is found out that these cells are efficacious in treating brain infarction. It is also found out that human and mouse bone marrow stem cells have the same effect. Namely, mesenchymal cells such as bone marrow cells, umbilical cord blood cells or peripheral blood cells are usable as a drug for intravenous administration against cranial nerve diseases.

Cell fraction containing cells capable of differentiating into neural cells

Method for inducing differentiation mesodermal stem cells, es cells or immortalized cells into nervous system cells

Mesodermal stem cells or ES cells, prepared from the mononuclear cell fraction isolated from bone marrow fluid or umbilical blood, were found to differentiate into neural stem cells, neurons, or glial cells when cultured in a basal culture medium. In addition, the differentiation of the mesodermal stem cells or ES cells into neural cells was promoted through the addition of an ischemic brain extract to the above-mentioned basal culture medium. Furthermore, the neural cells obtained using the above-described method for inducing differentiation were revealed to have neural regeneration potency in a brain infarction model, a dementia model, a spinal cord injury model and a demyelination model. In addition, according to the present invention, mesodermal stem cells can be differentiated into neural cells by immortalizing the mesodermal stem cells by highly expressing or activating an immortalization gene in the mesodermal stem cells and culturing the cells under an appropriate condition. The methods of the present invention are very useful in the medical field of neural regeneration.

Observation device

[Object] To provide an observation device capable of obtaining a good optical image by keeping contrast constant while eliminating the necessity of work for adjusting the distance from a phase contrast microscope to an observation target.[Solution] An observation device 10 includes a microscope 12. The microscope 12 includes an illumination light beam source 50, an illumination optical system 51, and an observation optical system 52 forming an optical image of an observation target 28 from reflected light beams 62 obtained by reflection of illumination light beams 61 by the observation target 28. The observation optical system 52 includes a phase plate 57 changing the phase of directly reflected light beams 62A reflected on a reflection surface 49a among the reflected light beams 62. Both the illumination optical system 51 and the observation optical system 52 are arranged under the observation target 28. The observation device 10 includes an image pickup device 53 photoelectrically converting the optical image obtained by the observation optical system 52 to create image data of the observation target 28 and a display device 38 displaying the image data. The illumination light beam 61 emitted from the illumination optical system 51 is a collimated light beam.

Autoserum-containing bone marrow cell culture system, autoserum-containing bone marrow cell culture method, and method for producing medicinal composition comprising autoserum-containing cultured bone marrow cells as active ingredient

Medicament for treating cerebral infarction

Provided is a novel means for: reducing the risk of cerebral hemorrhage as a result of recanalization therapy for occluded blood vessels (e.g., administration of medical drugs including thrombolytic agent, platelet aggregation inhibitor, and blood coagulation inhibitor, or physical removal of blood clots); and more effectively treating ischemic vascular disorders. The present invention is a mesenchymal stem cell-containing medical drug for treating ischemic vascular disorders, characterized by being concurrently used with recanalization therapy for occluded blood vessels. More specifically, the present invention is a medical drug for treating ischemic vascular disorders, characterized by reducing the risk of cerebral hemorrhage as a result of recanalization therapy for occluded blood vessels and by extending the period during which the medical drug can be applied.

Synapse formation agent

The present invention relates to a synapse formation promoter and a brain plasticity promoter comprising CD24 negative mesenchymal stem cells prepared from a patient's own bone marrow aspirate and treatment of dementia, chronic-phase cerebral infarction, chronic-phase spinal cord injury, mental diseases, and the like using the synapse formation promoter and brain plasticity promoter.

Synapse formation agent

The present invention relates to a synapse formation promoter and a brain plasticity promoter comprising CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow aspirate and treatment of dementia, chronic-phase cerebral infarction, chronic-phase spinal cord injury, mental diseases, and the like using the synapse formation promoter and brain plasticity promoter.

Pharmaceutical composition for treating amyotrophic lateral sclerosis

The present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis. More specifically, the present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis, wherein the pharmaceutical composition comprises mesenchymal stem cells and is intravenously administered.

Medicament for treating cerebral infarction

Provided is a novel means for: reducing the risk of cerebral hemorrhage as a result of recanalization therapy for occluded blood vessels (e.g., administration of medical drugs including thrombolytic agent, platelet aggregation inhibitor, and blood coagulation inhibitor, or physical removal of blood clots); and more effectively treating ischemic vascular disorders. The present invention is a mesenchymal stem cell-containing medical drug for treating ischemic vascular disorders, characterized by being concurrently used with recanalization therapy for occluded blood vessels. More specifically, the present invention is a medical drug for treating ischemic vascular disorders, characterized by reducing the risk of cerebral hemorrhage as a result of recanalization therapy for occluded blood vessels and by extending the period during which the medical drug can be applied.

Method and kit for evaluating prognosis, distant recurrence risk and invasion of glioma, and pharmaceutical composition for treating glioma

Method for management of cell processing process, and processing tool kit therefor

Method for management of cell processing process, and processing tool kit therefore Disclosed is a method of managing a cell processing process to be performed in an aseptic manipulation area by use of a processing material comprising a biological material associated with a specific sample and a processing tool kit prepared to allow a set of selectively combined processing tools to be enclosed therein. The method comprises: pre-appending, to a wireless communication device attached to the processing tool kit, kit identification data associated with tool identification data uniquely assigned to each of the combined processing tools enclosed in the processing tool kit; pre-storing, in a data processing unit, cell processing process- instruction data associated with respective identification data, such as a plurality of biological-material identification data and a plurality of the kit identification data; causing a wireless reading unit to read the kit identification data; and causing the data processing unit to choose an arbitrary one of the plurality of kit identification data associated with the process-instruction data, and cross-check the read kit identification data with the arbitrary kit identification data, whereby, when the two cross-checked data are coincident with each other, an operator is permitted to carry the processing tool kit into the aseptic processing area. The method of the present invention can manage a processing material quickly and accurately without error to prevent biological hazards. The present invention also provides a processing tool kit for use in the method.

細胞調製を行う際の細胞調製管理方法及び細胞調製管理システム

【課題】　細胞調製で取り扱われる膨大な数の容器などの資材を含む原材料を的確にミスなく管理することによって、生体に与える危険を未然に回避する細胞調製管理方法及びシステムである。 【解決手段】　検体に関連付けられた生物由来の原料と資材を含む原材料を用いて無菌操作区域で細胞調製する際に、原料識別情報、資材識別情報などの識別情報の各々と関連付けた細胞調製指示情報が情報処理装置に格納され、無線読取装置が、無菌操作区域に搬出入される原材料に装着された無線通信装置に担持させた識別情報を読取り、情報処理装置が、前記読取られた識別情報と前記細胞調製指示情報に関連付けられた対応する識別情報とを照合し、両者が一致したか否かを照合情報として出力し、前記照合情報が一致したことが確認された場合に細胞調製が継続されるようにしたことを特徴とする細胞調製管理方法及びシステムである。

Observation device

An observation device includes a microscope. The microscope includes an illumination light beam source, an illumination optical system, and an observation optical system forming an optical image of an observation target from reflected light beams obtained by reflection of illumination light beams by the observation target. The observation optical system includes a phase plate changing the phase of directly reflected light beams reflected on a reflection surface among the reflected light beams. Both the illumination optical system and the observation optical system are arranged under the observation target. The observation device includes an image pickup device photoelectrically converting the optical image obtained by the observation optical system to create image data of the observation target and a display device displaying the image data. The illumination light beam emitted from the illumination optical system is a collimated light beam.